Brevan Howard Capital Management LP Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Brevan Howard Capital Management LP grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 341.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 47,326 shares of the biopharmaceutical company's stock after acquiring an additional 36,599 shares during the quarter. Brevan Howard Capital Management LP owned about 0.08% of Agios Pharmaceuticals worth $1,555,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Balyasny Asset Management L.P. bought a new position in Agios Pharmaceuticals in the 4th quarter valued at about $8,151,000. Bank of America Corp DE increased its stake in Agios Pharmaceuticals by 21.6% in the fourth quarter. Bank of America Corp DE now owns 404,902 shares of the biopharmaceutical company's stock valued at $13,305,000 after acquiring an additional 71,827 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in Agios Pharmaceuticals by 3.9% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company's stock worth $30,146,000 after purchasing an additional 34,689 shares during the last quarter. Gallagher Fiduciary Advisors LLC lifted its stake in Agios Pharmaceuticals by 7.6% during the fourth quarter. Gallagher Fiduciary Advisors LLC now owns 11,110 shares of the biopharmaceutical company's stock worth $365,000 after purchasing an additional 788 shares during the last quarter. Finally, Caligan Partners LP boosted its holdings in shares of Agios Pharmaceuticals by 8.0% in the 4th quarter. Caligan Partners LP now owns 626,280 shares of the biopharmaceutical company's stock valued at $20,580,000 after purchasing an additional 46,563 shares in the last quarter.

Insider Activity at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now owns 149,220 shares in the company, valued at $3,864,798. This represents a 4.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.30% of the stock is currently owned by insiders.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO traded up $1.53 during mid-day trading on Monday, hitting $28.85. The company had a trading volume of 144,271 shares, compared to its average volume of 694,847. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The firm has a fifty day moving average price of $29.23 and a 200 day moving average price of $37.17. The company has a market capitalization of $1.67 billion, a PE ratio of 2.54 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the company. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price on the stock. Finally, Scotiabank cut their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.